06:07 AM EDT, 09/09/2026 (MT Newswires) -- Elicera Therapeutics (ELIC.ST) is set to advance its Carma clinical study's phase 2a trial with the highest dosage of its B-cell lymphoma therapy ELC-301 following the Data Safety and Monitoring Board's final review. The clinical-stage cell and gene therapy company said Wednesday that the start of the phase 2a study is still subject to the approval of the Swedish Medical Products Agency. Results from the phase 1 trial showed that 11 patients evaluated had achieved disease control, with no disease progression one month after treatment, while 10 achieved an objective tumor response, according to the company.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.